Geovax reports third quarter 2023 financial results and provides business update

Significant progress towards data milestones in phase 2 program of geo-cm04s1, next-generation covid-19 vaccine gedeptin ® clinical data from phase 1/2 study presented at aacr-ahns head and neck cancer conference showing safe administration and tumor reduction multi-product license secured for probiogen's age1.cr.pix® suspension cell line to enhance manufacturing capabilities of mva-based vaccine portfolio company to host conference call and webcast today at 4:30 p.m. et atlanta, ga, nov. 08, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter ended september 30, 2023 and provided a business update.
GOVX Ratings Summary
GOVX Quant Ranking